Cargando…
Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
• Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refract...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292902/ https://www.ncbi.nlm.nih.gov/pubmed/32551353 http://dx.doi.org/10.1016/j.gore.2020.100581 |